NCT00793585

A Controlled Study of Uric Acid on the Progression of IgA Nephropathy

A Prospective, Randomized Controlled Study of Uric Acid on the Progression of IgA Nephropathy

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 40 (actual)
• Sponsor: Sun Yat-sen University · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

This prospective, randomized controlled study will evaluate the effect of uric acid on the progression of IgA nephropathy.

Detailed description

It has been reported that hyperuricemia is a risk factor for progression of IgAN. This will be a prospective, randomized study. Eligible IgAN patients will be randomized into the treatment group and the control group. Patients in treatment group will receive allopurinol and usual therapy. Patients in control group will receive usual therapy with placebo. If with hypertension, add the CCB and the β-blocker. Fasting uric acid, serum creatinine, albumin, routine blood test, urine microscopy and dipstick, proteinuria of 24 hours and blood pressure will be measured every month. After followed-up for 6 months, the curative effect of Allopurinol on blood pressure, proteinuria and the progression of IgA nephropathy will be evaluated.

Conditions

• IgA Nephropathy

Interventions

Type	Name	Description
DRUG	allopurinol	Patients will receive the lifestyle modification and treatment of allopurinol (300 mg /d) and lifestyle modification for 4 weeks; when the UA level \< 6mg/dl , the dosage changed to 200mg/d.
OTHER	continue their usual therapy	Patients will receive lifestyle modification and continue their usual therapy.

Timeline

• Start date: 2007-07-01
• Primary completion: 2009-06-01
• Completion: 2009-06-01
• First posted: 2008-11-19
• Last updated: 2016-05-25
• Results posted: 2011-07-01

Locations

1 site across 1 country: China